The Bull Rankings scorecard — our quality-growth score is 79.4 / 100, built from three pillars scored 0–100: Quality 90, Growth 90, Value 62 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 24% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
DexCom’s current price is a fair bet on a high‑quality, high‑growth business that already commands a premium. The Bull Rankings model gives it a 79.4/100 quality‑growth score, with Quality 90 as the strongest pillar and Value 62 as the softest. A 90 in Quality tells us the company’s earnings are stable, its margins are healthy, and its free‑cash‑flow generation is robust. The 62 in Value means the stock sits on the cheaper side of its sector peers, yet the P/E of 33.5 is still above the healthcare median, reflecting the market’s willingness to pay for growth. Three figures underline the case: a 20.1% profit margin, a 38.1% ROE, and a 15.5% revenue growth over the last twelve months. These numbers show a business that is both profitable and expanding, justifying the premium it currently trades at.
What the business actually is
DexCom sells continuous glucose monitoring (CGM) systems that let patients track blood sugar in real time. Its flagship products—Dexcom G7 and G7 15 Day—are integrated CGM systems that replace fingersticks. The G6 line remains a strong revenue driver, while Dexcom ONE+ offers a finger‑stick replacement for treatment decisions. For non‑insulin users, Stelo targets adults with prediabetes and Type 2 diabetes. The company also provides Dexcom Share, a remote monitoring platform, and the Dexcom Follow app, which helps clinicians manage patients remotely. End users are endocrinologists, physicians, and diabetes‑care providers, with a growing customer base in the United States and internationally.
Why it can (or can't) keep compounding
The moat is built on technology, data, and network effects. DexCom’s CGM systems generate continuous, high‑resolution glucose data that clinicians can use to tailor therapy. The profit margin of 20.1% and ROE of 38.1% indicate that the company can extract value from each dollar of sales, a sign that competitors cannot easily replicate the same economics. The Durable high returns signal from the model confirms that capital deployed in the business is earning a premium. Moreover, the company’s buying back stock signal shows confidence in its cash‑flow generation and a willingness to return value to shareholders, which further tightens the capital structure and supports future growth.
The valuation question
At a P/E of 33.5, DexCom trades above the healthcare median, but its Value 62 suggests it is still cheaper than many peers. The reverse‑DCF implied growth—24% a year in year 1, tapering to 4% by year 10—is higher than the trailing revenue growth of 15.5%. This means the market already prices in a significant optimism about future expansion. If the company can sustain a growth rate closer to the implied 24% in the near term, the current price is justified. However, if revenue growth stalls near 15%, the premium may be unwarranted.
The bear case
The weakest pillar, Value 62, signals that the stock is not a bargain. A P/E of 33.5 above the sector median indicates that investors are paying more for each dollar of earnings than they would for a comparable medical‑device firm. If the company fails to accelerate revenue growth beyond 15.5%, the implied 24% growth will be over‑optimistic, and the price will adjust downward. A concrete trigger would be a decline in profit margin below 20% or a drop in ROE below 38%, both of which would erode the quality advantage that justifies the premium.
What would change our mind
- Revenue growth falling below 12% YoY would suggest the market’s optimism is misplaced.
- Profit margin slipping under 18% would weaken the quality pillar and erode the moat.
- A P/E dropping below 30—the threshold that aligns the stock with the healthcare median—would shift the Value pillar into a more favorable range, potentially turning the stock into a value play rather than a growth bet.
If any of these conditions materialize, the thesis would need to be revisited, as the current price would no longer reflect a high‑quality, high‑growth opportunity.